Bio Medica Laboratories Ltd IPO Day 1 Subscription Status, GMP Today, Review & Analysis
The Bio Medica Laboratories Ltd IPO opened for subscription on 21 May 2026 and has started gaining attention among SME IPO investors. The company operates in the pharmaceutical and healthcare manufacturing sector and is engaged in manufacturing pharmaceutical formulations and healthcare products for domestic markets.
The IPO is being closely tracked because healthcare and pharma sector companies continue to attract strong long-term investor interest. Day 1 subscription data shows moderate participation, while grey market premium (GMP) trends indicate cautious but stable market sentiment ahead of listing.
Bio Medica Laboratories Ltd IPO Important Dates
IPO Open Date: 21 May 2026
IPO Close Date: 25 May 2026
Tentative Allotment Date: 26 May 2026
Refund Initiation: 27 May 2026
Tentative Listing Date: 29 May 2026
Exchange: NSE SME
Bio Medica Laboratories Ltd IPO Price Band
Price Band: ₹132 to ₹139 per share
Face Value: ₹10 per share
Issue Size: ₹52.43 Crore
Fresh Issue: ₹47.19 Crore
Offer for Sale: ₹5.24 Crore
Lot Size: 1,000 Shares
Minimum Investment: ₹2,78,000
Registrar: Skyline Financial Services Pvt Ltd
Bio Medica Laboratories Ltd IPO Day 1 Subscription Status
According to available market data, the IPO has received a moderate response on Day 1. Qualified Institutional Buyers (QIBs) showed stronger participation compared to retail and HNI categories, indicating institutional confidence in the company’s long-term business potential.
Market experts believe subscription momentum may improve during the remaining bidding days if overall market conditions remain positive.
Retail Category: Around 1.09x
HNI/NII Category: Around 0.03x
QIB Category: Around 15.94x
Total Subscription: Around 0.72x
Bio Medica Laboratories Ltd IPO GMP Today
According to grey market reports, the IPO is currently trading with flat to limited GMP in the unofficial market. Investors are showing cautious optimism while waiting for stronger subscription demand and listing expectations.
Current GMP: ₹0 to ₹4
Estimated Listing Price: ₹139 to ₹143
Estimated Listing Gain: Up to 3%
Grey market premium is unofficial and can fluctuate rapidly depending on investor demand and market conditions before listing day.
About Bio Medica Laboratories Limited
Bio Medica Laboratories Limited is engaged in the manufacturing and marketing of pharmaceutical formulations and healthcare products. The company offers multiple healthcare and pharmaceutical products catering to different therapeutic categories.
The company focuses on quality manufacturing, operational efficiency, and expansion of its healthcare product portfolio to strengthen its market presence across India.
The company operates in:
- Pharmaceutical formulations manufacturing
- Healthcare product development
- Medicine distribution and supply
- Contract pharmaceutical manufacturing
- Healthcare and wellness product solutions
The company’s manufacturing facilities are equipped with modern production systems and quality control infrastructure to maintain healthcare standards.
Objectives of the IPO
- Working capital requirements
- Manufacturing capacity enhancement
- Business expansion activities
- General corporate purposes
Financial Performance
Bio Medica Laboratories Limited has shown strong financial growth during FY25 compared to FY24, supported by increasing healthcare product demand and improved operational performance.
Revenue FY24: ₹15.34 Crore
Revenue FY25: ₹38.33 Crore
Net Profit FY24: ₹2.50 Crore
Net Profit FY25: ₹9.79 Crore
EBITDA Margin: Around 47%
ROE: Around 23%
Strong profitability growth and improved revenue performance are among the key factors supporting investor attention toward the IPO.
Strengths of Bio Medica Laboratories Ltd IPO
- Strong pharmaceutical sector growth opportunities
- Healthy financial growth in FY25
- Improved profitability margins
- Quality-focused manufacturing operations
- Strong QIB participation on Day 1
- Expanding healthcare product portfolio
Risks Investors Should Consider
- SME IPOs generally carry high volatility
- Grey market premium remains limited
- Regulatory risks in pharmaceutical sector
- Competition from established pharma companies
- Weak HNI participation on Day 1
Should You Apply for Bio Medica Laboratories Ltd IPO?
The IPO may attract investors looking for opportunities in the growing pharmaceutical and healthcare industry. Strong financial growth, improving profitability, and healthy institutional participation are positive indicators for the company’s long-term potential.
However, muted GMP trends and moderate Day 1 subscription figures indicate cautious short-term market sentiment. Investors should carefully evaluate SME IPO risks and investment horizon before investing.
For latest GMP updates, subscription status, allotment details, and listing updates, investors can regularly follow the Bio Medica Laboratories Ltd IPO.
